Holen Sie sich die Stockscreener-App
71.06
1.78%
1.24
Handel nachbörslich:
70.50
-0.56
-0.79%
Schlusskurs vom Vortag:
$69.82
Offen:
$69.67
24-Stunden-Volumen:
897.68K
Relative Volume:
0.54
Marktkapitalisierung:
$5.93B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
9.1852
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
-2.50%
1M Leistung:
-7.50%
6M Leistung:
+3.02%
1J Leistung:
+40.52%
1-Tages-Spanne:
$68.02
$71.45
1-Wochen-Bereich:
$68.02
$74.03
52-Wochen-Spanne:
$48.27
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
71.06 | 5.89B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics (NASDAQ:PTCT) Director Sells 12,500 Shares - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) director sells 25,000 shares in 10b5-1 trade - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Gains Attention After Results - Kalkine Media
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920 - Sahm
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,813 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) CLO sells 2,813 shares under 10b5-1 plan - Stock Titan
PTC Therapeutics (NASDAQ: PTCT) holder plans 50,000-share resale - Stock Titan
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
PTC Therapeutics (NASDAQ: PTCT) insider lines up $201,692 share sale - Stock Titan
Price to earnings forward of PTC Therapeutics, Inc. – BX:P91 - TradingView
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal - MarketBeat
The week in pharma: action, reaction and insight – week to August 14, 2026 - The Pharma Letter
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Is Maintained at Overweight by Barclays - Moomoo
Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - Sahm
PTCT Maintained by Barclays -- Price Target Raised to $122 - GuruFocus
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - Dealbreaker
Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130 - Moomoo
PTC takes a chance on Sangamo’s Fabry disease gene therapy - BioPharma Dive
PTCT Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $109 - GuruFocus
PTC to Acquire Sangamo’s Fabry Disease Gene Therapy - Contract Pharma
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy - TipRanks
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale - BioSpace
Form 8K PTC Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
PTC to expand rare disease portfolio with ST-920 buy - The Pharma Letter
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction - Endpoints News
PTC THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $115 FROM $100 - Bitget
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners - The Business Journals
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 - Investing.com
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 By Investing.com - Investing.com Nigeria
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program - PR Newswire
How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing - Stock Traders Daily
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment - simplywall.st
Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped? - Sahm
Don't Ignore The Insider Selling In PTC Therapeutics - Moomoo
Have PTC Therapeutics Insiders Been Selling Stock? - simplywall.st
Zacks Research Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold - MarketBeat
PTC Therapeutics Inc (PTCT) Stock News Today - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock By Investing.com - Investing.com South Africa
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock - Investing.com
Bank of America Corp DE Raises Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 10,292 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CEO sells 10,292 shares to cover taxes - Stock Titan
PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases - finance.yahoo.com
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCHMERTZLER MICHAEL | Director |
Aug 20 '26 |
Sale |
71.11 |
12,500 |
888,858 |
1,361,594 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Aug 17 '26 |
Option Exercise |
25.69 |
2,813 |
72,266 |
108,085 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Aug 17 '26 |
Sale |
72.57 |
2,813 |
204,127 |
105,272 |
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):